8-K current report · filed Sep 14, 2026

VERACYTE, INC. (VCYT) 8-K Current Report: September 14, 2026

Item 1.01Item 2.01Item 7.01VCYT overview

Short answer

VERACYTE, INC. (VCYT) filed an 8-K current report with the SEC on September 14, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 7.01 (Regulation FD Disclosure). Veracyte acquired Convergent Genomics, adding UroAmp and urine tumor DNA technology for bladder cancer diagnostics.

VERACYTE, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Veracyte acquired Convergent Genomics, adding UroAmp and urine tumor DNA technology for bladder cancer diagnostics
  • $150 million upfront cash consideration, subject to customary purchase price adjustments
  • Up to $30 million additional cash tied to UroAmp publication and reimbursement milestones
  • Convergent becomes a wholly owned subsidiary, expanding Veracyte’s diagnostic pipeline and commercialization obligations

Item 2.01 · Completion of Acquisition or Disposition of Assets

  • Veracyte completed its acquisition of Convergent on September 14, 2026
  • Transaction executed under the previously disclosed Merger Agreement
  • Acquisition may expand Veracyte’s diagnostic portfolio, subject to terms disclosed under Item 1.01

Item 7.01 · Regulation FD Disclosure

  • Veracyte completed its acquisition of Convergent on September 14, 2026
  • Acquisition marks a strategic expansion, with financial and operational details in Exhibit 99.1
  • Investors should review Exhibit 99.1 for purchase terms, integration plans and expected business impact

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other VERACYTE, INC. 8-K filings

Get the next VCYT 8-K as it lands

Follow VCYT for push alerts, or ask the research agent what this filing means.